A5045975331- Epilepsy research and treatment
- Pharmacological Effects and Toxicity Studies
- Neuroscience and Neuropharmacology Research
- Tuberous Sclerosis Complex Research
- EEG and Brain-Computer Interfaces
- Neonatal and fetal brain pathology
- Cardiac Arrest and Resuscitation
- Polyomavirus and related diseases
- Acute Ischemic Stroke Management
- Hemoglobinopathies and Related Disorders
- Antiplatelet Therapy and Cardiovascular Diseases
- Traumatic Brain Injury and Neurovascular Disturbances
- Long-Term Effects of COVID-19
- Bacterial Infections and Vaccines
- Venous Thromboembolism Diagnosis and Management
- Drug Transport and Resistance Mechanisms
- Metabolism and Genetic Disorders
- Psychosomatic Disorders and Their Treatments
- Glioma Diagnosis and Treatment
- Cystic Fibrosis Research Advances
- Anesthesia and Sedative Agents
- Healthcare Decision-Making and Restraints
- Histiocytic Disorders and Treatments
- Cerebrospinal fluid and hydrocephalus
- Psychiatric care and mental health services
Goethe University Frankfurt
2016-2025
University Hospital Frankfurt
2018-2025
Radboud University Medical Center
2023
Netherlands Food and Consumer Product Safety Authority
2023
Erasmus University Rotterdam
2023
Klinik und Poliklinik für Neurologie
2018-2023
Radboud University Nijmegen
2023
Goethe Institute
2018
Frankfurt Cancer Institute
2017
Summary Objective To evaluate factors predicting efficacy, retention, and tolerability of add‐on brivaracetam ( BRV ) in clinical practice. Methods A multicenter, retrospective cohort study recruiting all patients who started between February November 2016 with observation time 3 12 months. Results Of a total 262 (mean age 40, range 5–81 years, 129 male) treated , 227 (87%) were diagnosed to have focal, 19 (7%) idiopathic generalized 8 (3%) symptomatic epilepsy, whereas unclassified. The...
Abstract Background Assessment of quality life (QoL) has become an important indicator for chronic neurological diseases. While these conditions often limit personal independence and autonomy, they are also associated with treatment-related problems reduced expectancy. Epilepsy a tremendous impact on the QoL patients their families, which is underestimated by practitioners. The aim this work was to identify relevant factors affecting in adults epilepsy. Methods This cross-sectional,...
Abstract Background Advances in secondary stroke prevention, including direct oral anticoagulants (DOACs), dual antiplatelet therapies (DAPT), and cardiovascular risk management, have changed costs over the past decade. This study aimed to evaluate annual treatment trends drug-based prophylaxis after ischemic strokes. Methods Annual were evaluated using net per defined daily dosage (DDD) of discharge medications for patients treated 2020 at University Hospital Frankfurt, Germany. Evaluated...
The objective of this study was to evaluate effectiveness, retention, and tolerability brivaracetam (BRV) in genetic generalized epilepsies (GGE) clinical practice.A multicenter, retrospective cohort recruiting all patients that started BRV 2016 2017.A total 61 (mean age = 29.8, range 9-90 years, 41 female [67%]) were treated with BRV. They difficult control, 2.4 failed antiepileptic drugs (AEDs) the past, taking 1.9 AEDs on average at baseline. length exposure ranged from 7 days 24 months,...
Introduction: This study was designed to evaluate risk factors and incidence of epilepsy-related injuries accidents (ERIA) at an outpatient clinic a German epilepsy center providing healthcare mixed urban rural population over one million inhabitants. Methods: Data acquisition performed between 10/2013 09/2014 using validated patient questionnaire on socioeconomic status, course epilepsy, quality life (QoL), depression, associated with seizures or inadequate periictal patterns behavior...
Antiseizure medication (ASM) as monotherapy or in combination is the treatment of choice for most patients with epilepsy. Therefore, knowledge about typical adverse events (AEs) ASMs and other coadministered drugs (CDs) essential practitioners patients. Due to frequent polypharmacy, it often difficult clinically assess AE profiles differentiate influence CDs. This retrospective analysis aimed determine impact CDs on AEs clinical practice. The Liverpool Profile (LAEP) its domains were used...
Abstract Objective This study was undertaken to quantify epilepsy‐related costs of illness (COI) in Germany and identify cost‐driving factors. Methods COI were calculated among adults with epilepsy different etiologies severities. Multiple regression analysis applied determine any sociodemographic factors that serve as Results In total, 486 patients included, a mean age 40.5 ± 15.5 years (range = 18–83 years, 58.2% women). Mean 3‐month estimated at €4911, €2782, €2598 for focal, genetic...
Objective: To evaluate the efficacy and tolerability of brivaracetam (BRV) in a severely drug refractory cohort patients with epileptic encephalopathies (EE). Method: A multicenter, retrospective study recruiting all treated EE who began treatment BRV an enrolling epilepsy center between 2016 2017. Results: Forty-four (27 male [61%], mean age 29 years, range 6 to 62) were BRV. The retention rate was 65% at 3 months, 52% months 41% 12 months. time 5 resulted cumulative exposure 310 Three...
Abstract Objective This study was undertaken to calculate epilepsy‐related direct, indirect, and total costs in adult patients with active epilepsy (ongoing unprovoked seizures) Germany analyze cost components dynamics compared previous studies from 2003, 2008, 2013. analysis part of the Epi2020 study. Methods Direct indirect related were calculated a multicenter survey using an established validated questionnaire bottom‐up design human capital approach over 3‐month period late 2020....
This study was undertaken to evaluate retention and treatment characteristics of cenobamate (CNB) in patients with developmental epileptic encephalopathies (DEEs) clinical practice. multicenter, retrospective cohort recruited all DEEs who started CNB between October 2020 April 2023 at participating epilepsy centers. A total 41 (mean age = 28.3 ± 13.1 years, median 26 range 4-73 years; 24 male [58.5%]) were treated CNB. Of these, 33 had Lennox-Gastaut syndrome, seven tuberous sclerosis...
In randomised controlled trials, adjunctive cenobamate (CNB) has been shown to reduce seizure frequency in patients with drug-resistant focal epilepsy. Studies conducted real-world settings provide valuable complementary data further characterise the drug's profile. To assess efficacy, retention and tolerability of (CNB), identify factors that might predict these outcomes clinical treatment epilepsies. This multicentre, retrospective cohort study included all who began CNB between October...